I realise the two companies are not competitors and drawing comparisons between the two of which one is better is really a mute exercise.
However given one is over $200M mrkt cap and one will list at $14M , I think the market will come to realise the value of return from epat from $14m to $100M cap rather than say $200M to $500m, this will gain momentum once the management team are able to release news and promote the viability and value of epat multiple uses app.
Another differentiating point is with all due respect to the RAP team , I rate the experience and calibre of the new Epat management team ahead
But ultimately the market is king and valuation will be determined by the market , like it has done for RAP
- Forums
- ASX - By Stock
- Is this RAP v2.0?
I realise the two companies are not competitors and drawing...
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MNQ (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online